Pub Date : 2025-01-01DOI: 10.5114/pedm.2025.152598
Martyna R Gąsiorek, Marcin D Niedziela, Przemysława Jarosz-Chobot
Continuous glucose monitoring (CGM) systems have revolutionized diabetes management by providing real-time glycemic data, improving control, and reducing the risk of both acute and chronic complications. With an increasing range of CGM systems available on the market, selecting the most appropriate system has become a challenge for both patients and healthcare professionals. This narrative review aims to analyze the available CGM systems and identify the factors that influence the personalized selection of a CGM system for patients with diabetes, based on system functions and features. Factors influencing CGM choice are discussed, including patient age, fear of puncture, physical activity, aesthetics, and financial considerations.
{"title":"Personalization of continuous glucose monitoring system for diabetic patients in the Polish market in 2024.","authors":"Martyna R Gąsiorek, Marcin D Niedziela, Przemysława Jarosz-Chobot","doi":"10.5114/pedm.2025.152598","DOIUrl":"10.5114/pedm.2025.152598","url":null,"abstract":"<p><p>Continuous glucose monitoring (CGM) systems have revolutionized diabetes management by providing real-time glycemic data, improving control, and reducing the risk of both acute and chronic complications. With an increasing range of CGM systems available on the market, selecting the most appropriate system has become a challenge for both patients and healthcare professionals. This narrative review aims to analyze the available CGM systems and identify the factors that influence the personalized selection of a CGM system for patients with diabetes, based on system functions and features. Factors influencing CGM choice are discussed, including patient age, fear of puncture, physical activity, aesthetics, and financial considerations.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 2","pages":"75-79"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144776456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.5114/pedm.2025.155157
{"title":"Erratum to the article: Primary hyperparathyroidism in children: Insights from a single-center cohort, Pediatr Endocrinol Diabetes Metab 2025; 31 (2): 52-58, DOI: https://doi.org/10.5114/pedm.2025.152595.","authors":"","doi":"10.5114/pedm.2025.155157","DOIUrl":"10.5114/pedm.2025.155157","url":null,"abstract":"","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 3","pages":"141"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12612572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145507298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.5114/pedm.2025.158546
Piotr Zieliński, Piotr Czeczot, Karolina Góralczyk-Czeczot
This article examines the legal and ethical obligations of physicians towards minor patients with type 1 diabetes in situations where their legal representatives hinder or prevent treatment. This issue is gaining importance in the context of the observed increase in parents forgoing insulin therapy or follow-up visits in favor of alternative medicine. In such situations, physicians face a dilemma: how to reconcile the parents' right to decide on their child's treatment with their own obligation to protect the child's life and health. The study discusses the scope of physicians' obligations under the law, with particular emphasis on civil and criminal law, including the requirement to notify the family court. It also emphasizes the importance of taking conciliatory measures - such as a written request for the guardian to attend a visit with the child - as a form of early intervention before notifying the authorities. The conclusions point to the need to develop clear procedures for intervention in cases of minor patients with chronic diseases failing to report, to strengthen interinstitutional cooperation, and to provide health education for parents. The article aims to show that the physician's responsibility in such cases goes beyond the medical sphere - it also includes the obligation to respond legally and ethically to a threat to the child's well-being. The article draws on legal provisions and legal acts relevant to the issue under study. Legal literature, including commentaries and scholarly articles, was also analyzed. Documents and materials relevant to the topic were also considered. The study was conducted using a dogmatic method, allowing for a systematic interpretation of legal provisions. A literature review was also employed to organize the positions of the doctrine. Additionally, elements of comparative analysis of available sources were employed to better understand the issues under investigation.
{"title":"Obligations of a physician and the limits of his/her liability towards the attitudes of legal representatives that hinder or prevent the treatment of a minor patient with type 1 diabetes - legal and ethical aspects.","authors":"Piotr Zieliński, Piotr Czeczot, Karolina Góralczyk-Czeczot","doi":"10.5114/pedm.2025.158546","DOIUrl":"10.5114/pedm.2025.158546","url":null,"abstract":"<p><p>This article examines the legal and ethical obligations of physicians towards minor patients with type 1 diabetes in situations where their legal representatives hinder or prevent treatment. This issue is gaining importance in the context of the observed increase in parents forgoing insulin therapy or follow-up visits in favor of alternative medicine. In such situations, physicians face a dilemma: how to reconcile the parents' right to decide on their child's treatment with their own obligation to protect the child's life and health. The study discusses the scope of physicians' obligations under the law, with particular emphasis on civil and criminal law, including the requirement to notify the family court. It also emphasizes the importance of taking conciliatory measures - such as a written request for the guardian to attend a visit with the child - as a form of early intervention before notifying the authorities. The conclusions point to the need to develop clear procedures for intervention in cases of minor patients with chronic diseases failing to report, to strengthen interinstitutional cooperation, and to provide health education for parents. The article aims to show that the physician's responsibility in such cases goes beyond the medical sphere - it also includes the obligation to respond legally and ethically to a threat to the child's well-being. The article draws on legal provisions and legal acts relevant to the issue under study. Legal literature, including commentaries and scholarly articles, was also analyzed. Documents and materials relevant to the topic were also considered. The study was conducted using a dogmatic method, allowing for a systematic interpretation of legal provisions. A literature review was also employed to organize the positions of the doctrine. Additionally, elements of comparative analysis of available sources were employed to better understand the issues under investigation.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 4","pages":"220-226"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.5114/pedm.2025.155104
Zuzanna Gawlik, Konrad Kaleta, Martyna Wróblewska, Maria Szwarkowska, Ewelina Preizner-Rzucidło, Krystian Jażdżewski, Sebastian Wardak, Jerzy B Starzyk, Dominika M Januś
Aldosterone is synthesized in the adrenal zona glomerulosa via the action of the mitochondrial cytochrome P450 enzyme aldosterone synthase (CYP11B2) through sequential enzyme reactions. Pathogenic variants in CYP11B2 result in corticosterone methyloxidase type I deficiency (CMO I), an orphan condition with a potentially lethal electrolyte imbalance in infancy. We report the unique occurrence of CMO I with celiac disease in the first genetically confirmed Polish case of CMO I; a 15-year-old female, diagnosed initially in the neonatal period because of severe hyponatremia, hyperkalemia, metabolic acidosis, and failure to thrive. The patient's clinical course was complicated by protracted electrolyte abnormalities, poor weight gain, and eventual diagnosis of celiac disease, which temporally correlated with abnormal growth patterns. Extensive endocrine assessment, steroid profiling, and next-generation DNA sequencing revealed a homozygous pathogenic variant in CYP11B2 (c.1354G>A; p.Gly452Arg), confirming CMO type I.
{"title":"Aldosterone synthase deficiency due to homozygous CYP11B2 pathogenic variant with coexisting celiac disease: A case study and literature review.","authors":"Zuzanna Gawlik, Konrad Kaleta, Martyna Wróblewska, Maria Szwarkowska, Ewelina Preizner-Rzucidło, Krystian Jażdżewski, Sebastian Wardak, Jerzy B Starzyk, Dominika M Januś","doi":"10.5114/pedm.2025.155104","DOIUrl":"10.5114/pedm.2025.155104","url":null,"abstract":"<p><p>Aldosterone is synthesized in the adrenal zona glomerulosa via the action of the mitochondrial cytochrome P450 enzyme aldosterone synthase (CYP11B2) through sequential enzyme reactions. Pathogenic variants in CYP11B2 result in corticosterone methyloxidase type I deficiency (CMO I), an orphan condition with a potentially lethal electrolyte imbalance in infancy. We report the unique occurrence of CMO I with celiac disease in the first genetically confirmed Polish case of CMO I; a 15-year-old female, diagnosed initially in the neonatal period because of severe hyponatremia, hyperkalemia, metabolic acidosis, and failure to thrive. The patient's clinical course was complicated by protracted electrolyte abnormalities, poor weight gain, and eventual diagnosis of celiac disease, which temporally correlated with abnormal growth patterns. Extensive endocrine assessment, steroid profiling, and next-generation DNA sequencing revealed a homozygous pathogenic variant in CYP11B2 (c.1354G>A; p.Gly452Arg), confirming CMO type I.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 3","pages":"133-140"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12612578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145507307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Congenital hyperinsulinism (CHI) represents a complex group of genetic disorders causing inappropriate insulin secretion. We report the first case of severe CHI caused by a novel combination of HADH and GHSR mutations, leading to an unusually severe neurological phenotype. A male infant presented at 24 days of life with severe hypoglycemic seizures (0.3 mmol/l), inappropriate hyperinsulinemia (10.31 µUI/ml), and elevated C-peptide (2.64 µg/l). His clinical course was marked by progressive neurological deterioration, evolving from neonatal seizures to West syndrome at 12 months, and subsequently to Lennox-Gastaut syndrome at 3 years. Genetic analysis revealed a previously undescribed combination of a homozygous HADH deletion (5.25 kb, exons 3-4) and a heterozygous GHSR missense variant (c.611C>A, p.Ala204Glu). Therapeutic management was particularly challenging in a resource-limited setting, with unavailability of essential medications such as diazoxide. Despite intensive management with medium-chain triglyceride-enriched formula, levocarnitine, and nocturnal cornstarch, glycemic control remained suboptimal. At 7 years, the patient presents severe psychomotor delay (-4 SD for weight and height) and drug-resistant epilepsy. This case highlights the potential for severe phenotypes in digenic CHI and suggests synergistic effects between fatty acid metabolism and hormonal signaling pathways in glucose homeostasis, opening new perspectives for understanding complex forms of CHI.
{"title":"Severe congenital hyperinsulinism with progressive neurological deterioration due to novel HADH-GHSR digenic mutations: the first case report.","authors":"Azzeddine Laaraje, Abdelilah Radi, Aomar Agadr, Rachid Abilkassem","doi":"10.5114/pedm.2025.153731","DOIUrl":"10.5114/pedm.2025.153731","url":null,"abstract":"<p><p>Congenital hyperinsulinism (CHI) represents a complex group of genetic disorders causing inappropriate insulin secretion. We report the first case of severe CHI caused by a novel combination of HADH and GHSR mutations, leading to an unusually severe neurological phenotype. A male infant presented at 24 days of life with severe hypoglycemic seizures (0.3 mmol/l), inappropriate hyperinsulinemia (10.31 µUI/ml), and elevated C-peptide (2.64 µg/l). His clinical course was marked by progressive neurological deterioration, evolving from neonatal seizures to West syndrome at 12 months, and subsequently to Lennox-Gastaut syndrome at 3 years. Genetic analysis revealed a previously undescribed combination of a homozygous HADH deletion (5.25 kb, exons 3-4) and a heterozygous GHSR missense variant (c.611C>A, p.Ala204Glu). Therapeutic management was particularly challenging in a resource-limited setting, with unavailability of essential medications such as diazoxide. Despite intensive management with medium-chain triglyceride-enriched formula, levocarnitine, and nocturnal cornstarch, glycemic control remained suboptimal. At 7 years, the patient presents severe psychomotor delay (-4 SD for weight and height) and drug-resistant epilepsy. This case highlights the potential for severe phenotypes in digenic CHI and suggests synergistic effects between fatty acid metabolism and hormonal signaling pathways in glucose homeostasis, opening new perspectives for understanding complex forms of CHI.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 4","pages":"215-219"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.5114/pedm.2025.158543
Olga Kamińska-Jackowiak, Martyna Kolasa, Agata Chobot, Tiago Dos Santos
Introduction: The study aimed to systematically evaluate whether coronavirus disease (COVID-19) infection and/or vaccination act as environmental triggers for new-onset type 1 diabetes (T1D) in children and adolescents.
Material and methods: We will conduct a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. PubMed, Embase, Scopus, Web of Science, and Cochrane Library will be searched for studies from 2020 onward. Eligible studies must report new-onset T1D in individuals aged 0-19 years following confirmed SARS-CoV-2 infection or COVID-19 vaccination, with a clearly defined comparator group. Data will be extracted using the Population-Exposure-Comparator-Outcome (PECO) framework, aiming to capture diabetes incidence, diabetic ketoacidosis (DKA) severity, immunologic and genetic markers, direction of effect, and potential confounders. Risk of bias will be assessed with the Newcastle-Ottawa Scale, and GRADE will be used to assess certainty of evidence. A random-effects meta-analysis will be conducted if appropriate.
Expected results: We anticipate mapping the direction of effect (-, ¯, mixed, or = no difference) for each exposure-outcome pair, and identifying gaps related to immunologic markers, diagnostic timing, and confounding factors.
Conclusions: This review will provide a comprehensive synthesis of evidence on infection- and vaccine-triggered pediatric T1D, informing future prospective studies and surveillance efforts.
本研究旨在系统评估冠状病毒病(COVID-19)感染和/或疫苗接种是否作为儿童和青少年新发1型糖尿病(T1D)的环境触发因素。材料和方法:我们将按照PRISMA 2020指南进行系统评价和荟萃分析。PubMed, Embase, Scopus, Web of Science和Cochrane Library将从2020年开始搜索研究。符合条件的研究必须报告0-19岁确诊的SARS-CoV-2感染或COVID-19疫苗接种后新发T1D的个体,并明确定义比较组。数据将使用人群-暴露-比较者-结果(PECO)框架提取,旨在捕获糖尿病发病率,糖尿病酮症酸中毒(DKA)严重程度,免疫和遗传标记,作用方向和潜在混杂因素。偏倚风险将用纽卡斯尔-渥太华量表进行评估,GRADE将用于评估证据的确定性。如果合适,将进行随机效应荟萃分析。预期结果:我们期望绘制每个暴露-结果对的影响方向(-、¯、混合或=无差异),并确定与免疫标记物、诊断时间和混杂因素相关的差距。结论:本综述将提供关于感染和疫苗引发的儿科T1D的综合证据,为未来的前瞻性研究和监测工作提供信息。
{"title":"Environmental triggers of pediatric type 1 diabetes: A protocol for a systematic review and meta-analysis on the impact of COVID-19 infection and vaccination.","authors":"Olga Kamińska-Jackowiak, Martyna Kolasa, Agata Chobot, Tiago Dos Santos","doi":"10.5114/pedm.2025.158543","DOIUrl":"10.5114/pedm.2025.158543","url":null,"abstract":"<p><strong>Introduction: </strong>The study aimed to systematically evaluate whether coronavirus disease (COVID-19) infection and/or vaccination act as environmental triggers for new-onset type 1 diabetes (T1D) in children and adolescents.</p><p><strong>Material and methods: </strong>We will conduct a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. PubMed, Embase, Scopus, Web of Science, and Cochrane Library will be searched for studies from 2020 onward. Eligible studies must report new-onset T1D in individuals aged 0-19 years following confirmed SARS-CoV-2 infection or COVID-19 vaccination, with a clearly defined comparator group. Data will be extracted using the Population-Exposure-Comparator-Outcome (PECO) framework, aiming to capture diabetes incidence, diabetic ketoacidosis (DKA) severity, immunologic and genetic markers, direction of effect, and potential confounders. Risk of bias will be assessed with the Newcastle-Ottawa Scale, and GRADE will be used to assess certainty of evidence. A random-effects meta-analysis will be conducted if appropriate.</p><p><strong>Expected results: </strong>We anticipate mapping the direction of effect (-, ¯, mixed, or = no difference) for each exposure-outcome pair, and identifying gaps related to immunologic markers, diagnostic timing, and confounding factors.</p><p><strong>Conclusions: </strong>This review will provide a comprehensive synthesis of evidence on infection- and vaccine-triggered pediatric T1D, informing future prospective studies and surveillance efforts.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 4","pages":"204-208"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.5114/pedm.2025.155110
Idris Haji Ahmed, Farhad Shaker Armishty, Avan Saadi Saleh, Amir Kh Saleh, Solav Rashed Abdulqader, Shangist M Saleem, Bland Bayar Khaleel, Brisik H Rashad
Introduction: Type 1 diabetes mellitus (T1DM) is a common chronic childhood illness characterized by persistent hyperglycemia and glycosuria, caused by an insufficient amount of insulin due to the immune system attacking b cells in the pancreas. Autoantibodies against GAD65 are present in most individuals with T1DM. They can manifest years before the onset of the illness, acting as a prognostic indicator for the development of autoimmune diabetes. The study's objective was to evaluate glycated hemoglobin (HbA1c) levels and to determine the prevalence of glutamic acid decarboxylase 65 autoantibodies (anti-GAD65) in newly diagnosed Kurdish children with T1DM.
Material and methods: This cross-sectional study analyzed 148 patients with T1DM, aged 1-18 years, in Duhok, Kurdistan, Iraq. The study used blood glucose tests, anti-GAD65 antibodies, and HbA1c levels. The University of Zakho's ethical committee approved the study, and IBM SPSS 26 version software was used to analyze the data.
Results: The overall rate of autoantibody positivity was 70 (47.3%), while 78 (52.7%) did not have anti-GAD65 antibodies. The HbA1c was 11.33 ±2.33% on average among individuals who had just received a T1DM diagnosis. The study found no statistically significant association between anti-GAD65 antibody status and HbA1c levels. Although a trend toward higher HbA1c values was observed in anti-GAD65-negative patients, this did not reach statistical significance.
Conclusions: The study found autoantibody positivity in all age groups, with young people having the highest percentage. The results of this study should prompt further statistical analyses to support or negate the results of this study on a larger population scale.
{"title":"The prevalence of anti-GAD65 autoantibodies in children recently diagnosed with type 1 diabetes in Duhok City.","authors":"Idris Haji Ahmed, Farhad Shaker Armishty, Avan Saadi Saleh, Amir Kh Saleh, Solav Rashed Abdulqader, Shangist M Saleem, Bland Bayar Khaleel, Brisik H Rashad","doi":"10.5114/pedm.2025.155110","DOIUrl":"10.5114/pedm.2025.155110","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes mellitus (T1DM) is a common chronic childhood illness characterized by persistent hyperglycemia and glycosuria, caused by an insufficient amount of insulin due to the immune system attacking b cells in the pancreas. Autoantibodies against GAD65 are present in most individuals with T1DM. They can manifest years before the onset of the illness, acting as a prognostic indicator for the development of autoimmune diabetes. The study's objective was to evaluate glycated hemoglobin (HbA1c) levels and to determine the prevalence of glutamic acid decarboxylase 65 autoantibodies (anti-GAD65) in newly diagnosed Kurdish children with T1DM.</p><p><strong>Material and methods: </strong>This cross-sectional study analyzed 148 patients with T1DM, aged 1-18 years, in Duhok, Kurdistan, Iraq. The study used blood glucose tests, anti-GAD65 antibodies, and HbA1c levels. The University of Zakho's ethical committee approved the study, and IBM SPSS 26 version software was used to analyze the data.</p><p><strong>Results: </strong>The overall rate of autoantibody positivity was 70 (47.3%), while 78 (52.7%) did not have anti-GAD65 antibodies. The HbA1c was 11.33 ±2.33% on average among individuals who had just received a T1DM diagnosis. The study found no statistically significant association between anti-GAD65 antibody status and HbA1c levels. Although a trend toward higher HbA1c values was observed in anti-GAD65-negative patients, this did not reach statistical significance.</p><p><strong>Conclusions: </strong>The study found autoantibody positivity in all age groups, with young people having the highest percentage. The results of this study should prompt further statistical analyses to support or negate the results of this study on a larger population scale.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 3","pages":"83-88"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12612579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145507285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.5114/pedm.2025.152596
Junaidin Junaidin, Abdurachman Abdurachman, I Ketut Sudiana
Introduction: Meliponine honey, derived from stingless bees, has significant therapeutic potential due to its bioactive compounds, such as polyphenols and flavonoids, which contribute to its antioxidant and antidiabetic properties. However, the variations in honey quality based on bee species and geographical origin still require further exploration to maximize its benefits. This study aimed to evaluate the variations in antioxidant and antidiabetic properties of meliponine honey based on stingless bee species and their geographical origins.
Material and methods: This scoping review follows the Joanna Briggs Institute methodology, including a comprehensive literature search in major scientific databases such as PubMed, Scopus, DOAJ, Wiley Online, and Google Scholar. Data from relevant studies were extracted and analyzed using a thematic synthesis approach to identify patterns in the bioactivity of Trigona honey.
Results: A total of 23 articles met the inclusion criteria. The analysis revealed that the antioxidant properties of meliponine honey are influenced by phenolic and flavonoid content, which vary according to geographical origin, local flora, and bee species. The antidiabetic activity of the honey is associated with its ability to inhibit a-amylase and a-glucosidase enzymes and enhance insulin release. Honey from regions such as Kalimantan and Sarawak exhibited higher bioactive content compared to other areas.
Conclusions: Meliponine honey is a promising natural therapeutic agent for diabetes management, with its bioactive quality influenced by bee species, geographical origin, and botanical sources. This study supports further development to optimize the benefits of meliponine honey through holistic approaches and broader clinical trials.
{"title":"Comparison of antioxidant and antidiabetic properties of meliponine honey from different stingless bee species and origins: a scoping review.","authors":"Junaidin Junaidin, Abdurachman Abdurachman, I Ketut Sudiana","doi":"10.5114/pedm.2025.152596","DOIUrl":"10.5114/pedm.2025.152596","url":null,"abstract":"<p><strong>Introduction: </strong>Meliponine honey, derived from stingless bees, has significant therapeutic potential due to its bioactive compounds, such as polyphenols and flavonoids, which contribute to its antioxidant and antidiabetic properties. However, the variations in honey quality based on bee species and geographical origin still require further exploration to maximize its benefits. This study aimed to evaluate the variations in antioxidant and antidiabetic properties of meliponine honey based on stingless bee species and their geographical origins.</p><p><strong>Material and methods: </strong>This scoping review follows the Joanna Briggs Institute methodology, including a comprehensive literature search in major scientific databases such as PubMed, Scopus, DOAJ, Wiley Online, and Google Scholar. Data from relevant studies were extracted and analyzed using a thematic synthesis approach to identify patterns in the bioactivity of Trigona honey.</p><p><strong>Results: </strong>A total of 23 articles met the inclusion criteria. The analysis revealed that the antioxidant properties of meliponine honey are influenced by phenolic and flavonoid content, which vary according to geographical origin, local flora, and bee species. The antidiabetic activity of the honey is associated with its ability to inhibit a-amylase and a-glucosidase enzymes and enhance insulin release. Honey from regions such as Kalimantan and Sarawak exhibited higher bioactive content compared to other areas.</p><p><strong>Conclusions: </strong>Meliponine honey is a promising natural therapeutic agent for diabetes management, with its bioactive quality influenced by bee species, geographical origin, and botanical sources. This study supports further development to optimize the benefits of meliponine honey through holistic approaches and broader clinical trials.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"31 2","pages":"59-67"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144776442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.146861
Karolina Ruszkiewicz, Joanna Nazim
Introduction: Coeliac disease (CD) often coexists with type 1 diabetes mellitus (T1D). Children with double diagnosis are frequently asymptomatic, which raises the question of whether to introduce a strict gluten-free diet (GFD) or not.
Aim of the study: To summarise data on systemic consequences of coeliac disease in children with type 1 diabetes mellitus.
Material and methods: The PubMed database was searched for papers to identify meta-analyses, reviews and clinical trials focusing on children.
Results: Coeliac disease, like type 1 diabetes may adversely influence glycaemic control, growth, weight gain, lipid profile and bone health as well as increase the risk of vascular complications. A strict gluten-free diet, at least partly, prevents the development of systemic complications of both disorders.
Conclusions: Dietary restrictions do not have a negative impact on the quality of life of young diabetic patients hence a gluten-free diet with its multifaceted beneficial effects should be recommended to all children with diabetes and coeliac disease.
{"title":"Systemic consequences of coeliac disease in children with type 1 diabetes - is it worth following a gluten-free diet?","authors":"Karolina Ruszkiewicz, Joanna Nazim","doi":"10.5114/pedm.2024.146861","DOIUrl":"10.5114/pedm.2024.146861","url":null,"abstract":"<p><strong>Introduction: </strong>Coeliac disease (CD) often coexists with type 1 diabetes mellitus (T1D). Children with double diagnosis are frequently asymptomatic, which raises the question of whether to introduce a strict gluten-free diet (GFD) or not.</p><p><strong>Aim of the study: </strong>To summarise data on systemic consequences of coeliac disease in children with type 1 diabetes mellitus.</p><p><strong>Material and methods: </strong>The PubMed database was searched for papers to identify meta-analyses, reviews and clinical trials focusing on children.</p><p><strong>Results: </strong>Coeliac disease, like type 1 diabetes may adversely influence glycaemic control, growth, weight gain, lipid profile and bone health as well as increase the risk of vascular complications. A strict gluten-free diet, at least partly, prevents the development of systemic complications of both disorders.</p><p><strong>Conclusions: </strong>Dietary restrictions do not have a negative impact on the quality of life of young diabetic patients hence a gluten-free diet with its multifaceted beneficial effects should be recommended to all children with diabetes and coeliac disease.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 4","pages":"221-226"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.139367
Noman Ahmad, Sundus A Ansari, Nabil A Aleysae, Emily L G Heaphy, Mrouge M Sobaihi, Balgees A Alghamdi, Ali S Alzahrani
Introduction: Hereditary vitamin D resistant rickets (HVDRR) is a rare autosomal recessive disorder marked by end-organ resistance of 1,25-dihydroxyvitamin D secondary to various mutations in the vitamin D receptor gene. The currently accepted treatment modality involves bypassing the affected receptors in the gut with high-dose intravenous calcium. In a few limited case reports, cinacalcet, a calcimimetic, has been used as an adjunctive therapy.
Material and methods: Retrospective chart reviews were conducted to collect the clinical and biochemical data of 8 patients with HVDRR from 5 Saudi families. Four patients received only high-dose calcium, while the remaining 4 received adjuvant cinacalcet. Serum chemistry and PTH levels were measured before and during cinacalcet treatment. Gene sequencing was performed to identify the disease-causing mutation.
Results: All 8 patients exhibited alopecia and secondary hyperparathyroidism. Other clinical and biochemical features of rickets were present to varying degrees. Genetic analysis revealed 3 distinct mutations: a ligand-binding domain mutation in 3 unrelated patients, a ligand-binding domain mutation in 2 sisters, and a missense DNA-binding domain mutation in 3 brothers. While the overall response to therapy was variable, none of the 4 patients who received adjunctive cinacalcet developed hypocalcaemia, and there was some initial promise in improving serum PTH levels.
Conclusions: This series provides new insight into the clinical and biochemical characteristics as well as treatment responses in Saudi children with HVDRR. The findings suggest that cinacalcet is a safe and potentially valuable adjuvant in this understudied population; however, further research is required to verify these results.
导言:遗传性维生素 D 抵抗性佝偻病(HVDRR)是一种罕见的常染色体隐性遗传疾病,其特征是因维生素 D 受体基因的各种突变而导致 1,25-二羟维生素 D 的内脏器官抵抗。目前公认的治疗方法是通过大剂量静脉注射钙剂,绕过肠道中受影响的受体。在少数有限的病例报告中,西那卡西酮(一种钙离子拮抗剂)被用作辅助治疗:回顾性病历审查收集了来自 5 个沙特家庭的 8 名 HVDRR 患者的临床和生化数据。其中 4 名患者仅接受了大剂量钙剂治疗,其余 4 名患者接受了西那卡塞辅助治疗。在西那卡塞治疗前和治疗过程中测量了血清化学成分和 PTH 水平。进行基因测序以确定致病突变:所有8名患者均出现脱发和继发性甲状旁腺功能亢进。结果:8 名患者均出现脱发和继发性甲状旁腺功能亢进,并不同程度地表现出佝偻病的其他临床和生化特征。基因分析发现了3种不同的突变:3名无亲属关系的患者存在配体结合域突变,2个姐妹存在配体结合域突变,3个兄弟存在DNA结合域错义突变。虽然对治疗的总体反应不一,但接受西那卡塞辅助治疗的 4 名患者均未出现低钙血症,而且在改善血清 PTH 水平方面也取得了一些初步希望:该系列研究为了解沙特儿童 HVDRR 患者的临床和生化特征以及治疗反应提供了新的视角。研究结果表明,在这一研究不足的人群中,西那卡西酮是一种安全且有潜在价值的辅助治疗药物;但是,还需要进一步的研究来验证这些结果。
{"title":"Hereditary vitamin D resistant rickets (HVDRR) case series: phenotype, genotype, conventional treatment, and adjunctive cinacalcet therapy.","authors":"Noman Ahmad, Sundus A Ansari, Nabil A Aleysae, Emily L G Heaphy, Mrouge M Sobaihi, Balgees A Alghamdi, Ali S Alzahrani","doi":"10.5114/pedm.2024.139367","DOIUrl":"10.5114/pedm.2024.139367","url":null,"abstract":"<p><strong>Introduction: </strong>Hereditary vitamin D resistant rickets (HVDRR) is a rare autosomal recessive disorder marked by end-organ resistance of 1,25-dihydroxyvitamin D secondary to various mutations in the vitamin D receptor gene. The currently accepted treatment modality involves bypassing the affected receptors in the gut with high-dose intravenous calcium. In a few limited case reports, cinacalcet, a calcimimetic, has been used as an adjunctive therapy.</p><p><strong>Material and methods: </strong>Retrospective chart reviews were conducted to collect the clinical and biochemical data of 8 patients with HVDRR from 5 Saudi families. Four patients received only high-dose calcium, while the remaining 4 received adjuvant cinacalcet. Serum chemistry and PTH levels were measured before and during cinacalcet treatment. Gene sequencing was performed to identify the disease-causing mutation.</p><p><strong>Results: </strong>All 8 patients exhibited alopecia and secondary hyperparathyroidism. Other clinical and biochemical features of rickets were present to varying degrees. Genetic analysis revealed 3 distinct mutations: a ligand-binding domain mutation in 3 unrelated patients, a ligand-binding domain mutation in 2 sisters, and a missense DNA-binding domain mutation in 3 brothers. While the overall response to therapy was variable, none of the 4 patients who received adjunctive cinacalcet developed hypocalcaemia, and there was some initial promise in improving serum PTH levels.</p><p><strong>Conclusions: </strong>This series provides new insight into the clinical and biochemical characteristics as well as treatment responses in Saudi children with HVDRR. The findings suggest that cinacalcet is a safe and potentially valuable adjuvant in this understudied population; however, further research is required to verify these results.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 2","pages":"74-80"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}